

.....
(Original Signature of Member)

111TH CONGRESS
2D SESSION

H. R.

To establish the Office of the National Alzheimer’s Project.

IN THE HOUSE OF REPRESENTATIVES

Mr. MARKEY of Massachusetts introduced the following bill; which was referred to the Committee on _____

A BILL

To establish the Office of the National Alzheimer’s Project.

1 *Be it enacted by the Senate and House of Representa-*
2 *tives of the United States of America in Congress assembled,*

3 **SECTION 1. SHORT TITLE.**

4 This Act may be cited as the “National Alzheimer’s
5 Project Act”.

6 **SEC. 2. OFFICE OF THE NATIONAL ALZHEIMER’S PROJECT.**

7 (a) ESTABLISHMENT OF OFFICE.—There is estab-
8 lished in the Office of the Secretary of Health and Human
9 Services the Office of the National Alzheimer’s Project
10 (referred to in this Act as the “Office”).

1 (b) PURPOSE OF THE OFFICE.—The Office shall—

2 (1) accelerate the development of treatments
3 that would prevent, halt, or reverse the course of
4 Alzheimer’s;

5 (2) be responsible for the creation and mainte-
6 nance of an integrated national plan to overcome
7 Alzheimer’s;

8 (3) help to coordinate the health care and treat-
9 ment of citizens with Alzheimer’s;

10 (4) ensure the inclusion of ethnic and racial
11 populations at higher risk for Alzheimer’s or least
12 likely to receive care, in clinical, research, and serv-
13 ice efforts with the purpose of decreasing health dis-
14 parities in Alzheimer’s;

15 (5) coordinate with international bodies to inte-
16 grate and inform the fight against Alzheimer’s glob-
17 ally; and

18 (6) provide information and coordination of Alz-
19 heimer’s research and services across all Federal
20 agencies.

21 (c) DIRECTOR OF THE OFFICE.—

22 (1) APPOINTMENT.—The President shall ap-
23 point a Director of the Office.

24 (2) DUTIES OF THE DIRECTOR.—

1 (A) IN GENERAL.—The Director of the Of-
2 fice shall—

3 (i) oversee the creation and updating
4 of the national plan described in subpara-
5 graph (B);

6 (ii) use discretionary authority to
7 evaluate all Federal programs around Alz-
8 heimer's, including budget requests and
9 approvals; and

10 (iii) prepare and submit to the Presi-
11 dent the annual budget estimate for the
12 Office.

13 (B) NATIONAL PLAN.—The Director of the
14 Office shall carry out an annual assessment of
15 the Nation's progress in preparing for the esca-
16 lating burden of Alzheimer's, including both im-
17 plementation steps and recommendations for
18 priority actions based on the assessment.

19 (3) SERVICE BY DIRECTOR.—The Director of
20 the Office shall serve on the advisory board of the
21 Office of Science and Technology to promote re-
22 search efforts into mechanisms to slow and stop the
23 development of Alzheimer's for those at risk of de-
24 veloping the disease.

25 (d) ADVISORY COUNCIL.—

1 (1) IN GENERAL.—There is established in the
2 Office an Advisory Council on Alzheimer’s Research
3 and Treatment (referred to in this Act as the “Advi-
4 sory Council”).

5 (2) MEMBERSHIP.—

6 (A) FEDERAL MEMBERS.—The Advisory
7 Council shall be comprised of the following ex-
8 perts:

9 (i) A designee of the Centers for Dis-
10 ease Control and Prevention.

11 (ii) A designee of the Administration
12 on Aging.

13 (iii) A designee of the Centers for
14 Medicare & Medicaid Services.

15 (iv) A designee of the Indian Health
16 Service.

17 (v) A designee of the Office of the Di-
18 rector of the National Institutes of Health.

19 (vi) The Surgeon General.

20 (vii) A designee of the National
21 Science Foundation.

22 (viii) A designee of the Department of
23 Veterans Affairs.

24 (B) NON-FEDERAL MEMBERS.—In addi-
25 tion to the members outlined in subparagraph

1 (A), the Advisory Council shall include 12 ex-
2 pert members from outside the Federal Govern-
3 ment, which shall include—

4 (i) 2 Alzheimer patient advocates;

5 (ii) 2 Alzheimer caregivers;

6 (iii) 2 health care providers;

7 (iv) 2 representatives of State health
8 departments;

9 (v) 2 researchers with Alzheimer-re-
10 lated expertise in basic, translational, clin-
11 ical, or drug development science; and

12 (vi) 2 voluntary health association
13 representatives, including a national Alz-
14 heimer's disease organization that funds
15 research and has demonstrated experience
16 in care and patient services, and a State-
17 based advocacy organization that provides
18 services to families and professionals, in-
19 cluding information and referral, support
20 groups, care consultation, education, and
21 safety services.

22 (3) MEETINGS.—The Advisory Council shall
23 meet quarterly and such meetings shall be open to
24 the public.

1 (4) ADVICE.—The Advisory Council shall advise
2 the Director of the Office.

3 (5) ANNUAL REPORT.—The Advisory Council
4 shall provide to the Director of the Office—

5 (A) recommendations for information to be
6 included in the annual report to Congress by
7 the Office; and

8 (B) an annually updated national plan.

9 (e) ANNUAL REPORT.—The Director of the Office
10 shall submit to Congress—

11 (1) an annual report that includes an evalua-
12 tion of all nationally and federally funded efforts in
13 Alzheimer’s research, clinical care, institutional, and
14 home- and community-based programs and their
15 outcomes; and

16 (2) an annually updated national plan.

17 (f) SUNSET.—The Office shall expire on December
18 31, 2025.